wire - news in brief
« BACK
Health - 03.07.2020
Health - Social Sciences - 02.07.2020 
Launched on Antibody Prevalence and Impact of Coronavirus in Basel
A long-term study on the effects of the coronavirus pandemic is being carried out in the cantons of Basel-Stadt and Basel-Landschaft.
Pharmacology - Health - 01.07.2020
Health - Social Sciences - 01.07.2020
Administration - Health - 01.07.2020
Life Sciences - Health - 30.06.2020 
Next-Generation Sequencing to provide Precision medicine for Rare Metabolic Disorders
Advances in next-generation-sequencing technology that allow researchers to look at billions of pieces of genetic information are changing the way a disease is diagnosed. Correct identification of changes in the human genetic code responsible for rare metabolic disorders provides scientists and physicians with fact-based guidelines for the treatment.
Health - Pharmacology - 30.06.2020 
Meeting challenges through basic research
Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception.
Pharmacology - Health - 29.06.2020
Health - 29.06.2020
Pharmacology - Health - 29.06.2020
Health - 26.06.2020 
Problem solving, turbocharged
A healthcare solution born in an ETH student workshop has now entered mass production: the helpfulETH initiative is supporting hospitals during the coronavirus crisis by producing special face shields.
Pharmacology - Health - 26.06.2020
Pharmacology - Health - 26.06.2020
Life Sciences - Health - 25.06.2020 
Handing over the keys at Früebüel
Despite the coronavirus lockdown, the renovation and extension of Früebüel research station in Walchwil (Canton of Zug) was completed nearly on schedule.
Health - 25.06.2020 
Sooner or later, all data turns into health data
Anyone who owns a smartphone, uses social media or drives a "smart" car unwittingly reveals a lot about themselves.
Health - 24.06.2020
Health - 24.06.2020
Health - Pharmacology - 24.06.2020
Health - Pharmacology - 23.06.2020 
Breast Cancer Diagnostics: Spin-off Artidis announces successful clinical trial
The company Artidis, a University of Basel spin-off, has announced that it developed a test procedure that can detect breast cancer with a very high sensitivity. This is demonstrated by a clinical trial that investigated whether a nanomechanical biomarker of tissue samples is suitable for the diagnosis of breast cancer.
Health - Pharmacology - 22.06.2020
Pharmacology - Health - 19.06.2020
Health - 19.06.2020
Health - Pharmacology - 18.06.2020
Pharmacology - Health - 17.06.2020
Environment - Health - 16.06.2020
Health - Innovation - 16.06.2020
Health - Social Sciences - 16.06.2020 
Studying health issues "upon the people"
Emiliano Albanese, MD PhD is a Full professor at the USI Faculty of Biomedical Sciences and Director of the Institute of Public Health.
Health - 12.06.2020
Astronomy / Space Science - Health - 11.06.2020 
A Flight to Weightlessness from Dübendorf
The fourth parabolic flight organized by the UZH Space Hub takes off today from Dübendorf airfield. A reorganization taking into account Corona safety measures has made this possible.
Pharmacology - Health - 11.06.2020
Computer Science - Health - 05.06.2020
Pharmacology - Health - 05.06.2020
Health - Life Sciences - 05.06.2020 
Microbiology offers relief for "colicky" babies
Vanesa Rocha Martin is studying how bacteria can be used to treat infant colic. As part of her Pioneer Fellowship, she is now turning her findings into a first-line therapy with a proven effect.
Health - 04.06.2020
Health - Economics / Business - 04.06.2020
Health - Administration - 04.06.2020
Pharmacology - Health - 04.06.2020
Pharmacology - Health - 04.06.2020 
The key lies in the genes
Whether or not patients will respond to a drug can be determined in advance. In this way, side effects can be avoided and patients benefit, writes Ernst Hafen. "All things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison." These were the words of Paracelsus, a Swiss physician who recognised back in the 16 th century that every medicine has its benefits and risks, and that for a medicine to work, the individual dose is crucial.
Life Sciences - Health - 04.06.2020 
Heralding a new era in protein analytics
Systems biologist Paola Picotti receives this year's Rössler Prize for her groundbreaking work in the field of proteomics.
Health - 02.06.2020
Health - Pharmacology - 30.05.2020 
Switzerland's lockdown has sharply reduced the cases of COVID-19
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
Health - Social Sciences - 29.05.2020
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 28.05.2020
Pharmacology - Health - 28.05.2020
Health - Pedagogy - 27.05.2020
Pharmacology - Health - 27.05.2020
Pharmacology - Health - 27.05.2020
Health - Career - 27.05.2020
Health
Results 1 - 50 of 1920.
100%SwissDEM: everyone counts
The 100%SwissDEM awareness-raising campaign, which is aimed at giving voice to the elderly to encourage the discussion on research and issues related to the health and well-being of the population aged 65 and over, has reached the halfway point.
The 100%SwissDEM awareness-raising campaign, which is aimed at giving voice to the elderly to encourage the discussion on research and issues related to the health and well-being of the population aged 65 and over, has reached the halfway point.
A long-term study on the effects of the coronavirus pandemic is being carried out in the cantons of Basel-Stadt and Basel-Landschaft.
Advances in next-generation-sequencing technology that allow researchers to look at billions of pieces of genetic information are changing the way a disease is diagnosed. Correct identification of changes in the human genetic code responsible for rare metabolic disorders provides scientists and physicians with fact-based guidelines for the treatment.
Many scientists are currently undertaking work on the Sars-CoV-2 virus. But hundreds of projects supported by the SNSF are already contributing to finding answers to the current health crisis. In Switzerland and around the world, the novel coronavirus has become a priority for scientific research. Projects supported by the Swiss National Science Foundation (SNSF) are no exception.
A healthcare solution born in an ETH student workshop has now entered mass production: the helpfulETH initiative is supporting hospitals during the coronavirus crisis by producing special face shields.
Novartis Cosentyx gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and stro
EMA CHMP positive opinion paves way for Cosentyx to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and stro
Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglo
If approved, Xolair (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-immunoglo
Despite the coronavirus lockdown, the renovation and extension of Früebüel research station in Walchwil (Canton of Zug) was completed nearly on schedule.
Anyone who owns a smartphone, uses social media or drives a "smart" car unwittingly reveals a lot about themselves.
Coronavirus: Federal government to assume test costs, SwissCovid app to start on 25 June
In order to be able to respond rapidly to a renewed increase in the number of cases, testing should be conducted as widely as is possible and appropriate.
In order to be able to respond rapidly to a renewed increase in the number of cases, testing should be conducted as widely as is possible and appropriate.
The company Artidis, a University of Basel spin-off, has announced that it developed a test procedure that can detect breast cancer with a very high sensitivity. This is demonstrated by a clinical trial that investigated whether a nanomechanical biomarker of tissue samples is suitable for the diagnosis of breast cancer.
Computational pharmacology to combat the coronavirus
The ongoing COVID-19 pandemic has hit the world population hard, spreading throughout the globe since the beginning of the year and claiming more than 450,000 victims. The entire scientific community is engaged in an unprecedented effort to curb the progression of the disease, for which no specific cure is yet available.
The ongoing COVID-19 pandemic has hit the world population hard, spreading throughout the globe since the beginning of the year and claiming more than 450,000 victims. The entire scientific community is engaged in an unprecedented effort to curb the progression of the disease, for which no specific cure is yet available.
Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients bein
New collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients bein
Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis
FDA approval for Cosentyx is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis
"Huge forest fires put our health at risk"
After Australia, Siberia is burning, indicating that the frequency of such events is on the rise, with myriad dire consequences: devastated ecosystems, risk of desertification, CO2 emissions, toxic particles, further climate impacts..
After Australia, Siberia is burning, indicating that the frequency of such events is on the rise, with myriad dire consequences: devastated ecosystems, risk of desertification, CO2 emissions, toxic particles, further climate impacts..
Emiliano Albanese, MD PhD is a Full professor at the USI Faculty of Biomedical Sciences and Director of the Institute of Public Health.
The fourth parabolic flight organized by the UZH Space Hub takes off today from Dübendorf airfield. A reorganization taking into account Corona safety measures has made this possible.
US FDA approves updated Novartis Beovu label, to include additional safety information
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients 1 The upda
Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients 1 The upda
Lauzhack, or how to rescue your semester project in three days
The Lauzhack hackathon gave students a chance to redirect their semester projects towards issues related to the coronavirus.
The Lauzhack hackathon gave students a chance to redirect their semester projects towards issues related to the coronavirus.
Vanesa Rocha Martin is studying how bacteria can be used to treat infant colic. As part of her Pioneer Fellowship, she is now turning her findings into a first-line therapy with a proven effect.
Novartis PREVENT data show Cosentyx helps patients realize early and lasting relief in axial spondyloarthritis
Phase III PREVENT data show Cosentyx 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52 1 nr-axSpA is t
Phase III PREVENT data show Cosentyx 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52 1 nr-axSpA is t
Whether or not patients will respond to a drug can be determined in advance. In this way, side effects can be avoided and patients benefit, writes Ernst Hafen. "All things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison." These were the words of Paracelsus, a Swiss physician who recognised back in the 16 th century that every medicine has its benefits and risks, and that for a medicine to work, the individual dose is crucial.
Systems biologist Paola Picotti receives this year's Rössler Prize for her groundbreaking work in the field of proteomics.
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
